|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3555 SEK | +19.30% |
|
+28.80% | -96.44% |
| May. 22 | Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®? | CI |
| May. 16 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 |
Xbrane Biopharma AB (publ) reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was SEK 14.07 million compared to SEK 61.83 million a year ago. Net loss was SEK 97.41 million compared to SEK 58.4 million a year ago.
Basic loss per share from continuing operations was SEK 0.3. Diluted loss per share from continuing operations was SEK 0.3. Basic loss per share was SEK 0.3. Diluted loss per share was SEK 0.3.
| 1st Jan change | Capi. | |
|---|---|---|
| -96.44% | 43.27M | |
| +45.07% | 54.63B | |
| -7.02% | 39.92B | |
| +37.07% | 38.82B | |
| +12.74% | 26.86B | |
| -11.17% | 26.22B | |
| -22.12% | 18.78B | |
| +24.80% | 12.21B | |
| -0.05% | 12.16B | |
| +24.94% | 11.94B |
XBRANE BIOPHARMA AB 
